• About us
• Contact

Advertisement

Organisation › Details

Novartis AG (NYSE: NVS)

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 119,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world. *

 

	Start	1996-12-20 merged
	Group	Novartis (Group)
	Industry	LIFE SCIENCES
	Person	Narasimhan, Vasant (Vas) (Novartis 201408– Global Head Developm Novartis Pharma before Global Head Developm Vaccines
	Person 2	Reinhardt, Jörg (Novartis 201308– Board Chairman before Bayer 201008– CEO Bayer HealthCare AG before Novartis COO)
	Region	Basel BS
	Country	Switzerland
	City	4002 Basel BS
	Tel	41 61 324 8000
		Address record changed: 2024-01-05
Basic data	Employees	J: more than 100,0 (2018-12-31)
	Currency	USD
	Annual sales	47,498,000,000 (sales, net, continued operations, consolidated (2019) 2019-12-31)
	Profit	7,147,000,000 (2019-12-31)
	Cash	11,112,000,000 (2019-12-31)
		* Document for »About Section«:
		Record changed: 2025-03-16

Advertisement

More documents for Novartis (Group)

• [1] Isopmorphic Labs Ltd.. (2/18/25). "Press Release: Isomorphic Labs Announces Novartis Collaboration Expansion". London....
• [2] Anthos Therapeutics, Inc.. (2/11/25). "Press Release: Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 billion". Cambridge, MA....
• [3] Novartis AG. (2/11/25). "Press Release: Novartis Bolsters Late-stage Cardiovascular Pipeline with Agreement to Acquire Anthos Therapeutics for USD 925 Million Upfront". Basel....
• [4] Sanofi S.A.. (12/19/24). "Press Release: Jean-Paul Kress to Join Sanofi’s Board of Directors". Paris....
• [5] BioAge Labs, Inc.. (12/18/24). "Press Release: BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions". Richmond, CA....
• [6] Eckert & Ziegler SE. (12/13/24). "Press Release: Eckert & Ziegler Submits GalliaPharm for Approval by Japan’s Health Authority MHLW". Berlin....
• [7] Siemens Healthineers AG. (12/10/24). "Press Release: Siemens Healthineers Acquires Advanced Accelerator Applications Molecular Imaging"....
• [8] PTC Therapeutics, Inc.. (12/2/24). "Press Release: PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program". Warren, NJ....
• [9] Novartis AG. (11/21/24). "Press Release: Addressing Unmet Needs for Inherited Neuromuscular Diseases. Novartis Has Acquired Kate Therapeutics to Further Enhance and Strengthen Our Ongoing Efforts to Advance Gene Therapies for Patients"....
• [10] Agomab Therapeutics N.V.. (11/18/24). "Press Release: Agomab Announces the Appointment of Former Sandoz CFO Colin Bond to its Board of Directors". Antwerp....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.